The three receptors
The GLP-1 receptor agonists in clinical use activate a single receptor. Tirzepatide added a second, GIP. Retatrutide is designed to activate a third alongside those two: the glucagon receptor.
Adding glucagon-receptor activity is the notable design decision, because glucagon's classical role is raising blood glucose — the opposite of what a metabolic agent is usually trying to do. The rationale in the literature relates to glucagon's separate effects on energy expenditure and hepatic fat, with the co-agonism at GLP-1 and GIP intended to offset the glycaemic effect. Whether that balance holds across a broad population over long periods is one of the questions clinical development exists to answer.
| Receptor | Also targeted by |
|---|---|
| GLP-1 | Semaglutide, liraglutide, dulaglutide, tirzepatide |
| GIP | Tirzepatide |
| Glucagon | Retatrutide (investigational) |
Where development stands
Retatrutide has published phase 2 results and has progressed into later-stage clinical trials. That is a meaningful evidence base by the standards of this topic — it is real clinical data in humans, generated under protocol, with adverse events collected and reported.
It is also, precisely, why the compound is not approved: development is the process of establishing whether efficacy and safety hold up at scale and over time, and it has not concluded. Interim results are not a substitute for that conclusion, and drugs with encouraging phase 2 data do not uniformly reach approval.
What unapproved actually means here
There is no approved retatrutide product in any jurisdiction. There is no licensed manufacturer supplying it for human use, no prescribing information, no pharmacy dispensing channel, and no compounding pathway — compounding requires an approved active ingredient, which does not exist here.
Anything obtainable outside a clinical trial therefore sits outside every one of the systems that would normally establish what a vial contains: no regulated manufacturing, no assay verification, no purity or sterility guarantee, and no identity confirmation. The absence of a supply chain is not a paperwork gap — it is the absence of every mechanism by which the contents of a vial are known.
This page does not describe how to obtain, prepare or administer retatrutide, and deliberately contains no dosing information of any kind.
Key takeaways
- A triple agonist at the GLP-1, GIP and glucagon receptors — the third target is what distinguishes it.
- Genuine clinical trial data exists, which is unusual for compounds discussed in this space.
- Not approved anywhere. No licensed supply, no prescribing information, and no lawful compounding pathway.
- Without a regulated supply chain there is no mechanism establishing what any given vial contains.
Stop keeping this in your head.
Pep AI keeps your compounds, vials, schedule, injection sites and history in one place — and does the reconstitution math for you. Free on iOS and Android.
Frequently asked questions
Keep reading
This guide is general information for people already organising their own protocol. It is not medical advice, it does not recommend any compound or dose, and Pep AI is not a medical device. Talk to a qualified healthcare professional about anything you inject.
Published by the Pep AI team · Updated August 2026